CoChat

Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial

Open access
Durgam, Suresh, Earley, Willie, Li, Rui, Li, Dayong, Lu, Kaifeng, Laszlovszky, István, Fleischhacker, W. Wolfgang, Nasrallah, Henry A. · 2016 · Schizophrenia Research
Cited by 101

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Cariprazine, a dopamine D3/D2 receptor partial agonist with preference for D3 receptors, has demonstrated efficacy in randomized controlled trials in schizophrenia. This multinational, randomized, double-blind, placebo-controlled, parallel-group study evaluated the efficacy, safety, and tolerability of cariprazine for relapse prevention in adults with schizophrenia; total study duration was up to 97weeks. Schizophrenia symptoms were treated/stabilized with cariprazine 3-9mg/d during 20-week open-label treatment consisting of an 8-week, flexible-dose run-in phase and a 12-week fixed-dose stabilization phase. Stable patients who completed open-label treatment could be randomized to continued cariprazine (3, 6, or 9mg/d) or placebo for double-blind treatment (up to 72weeks). The primary efficacy parameter was time to relapse (worsening of symptom scores, psychiatric hospitalization, aggressive/violent behavior, or suicidal risk); clinical measures were implemented to ensure safety in case of impending relapse. A total of 264/765 patients completed open-label treatment; 200 eligible patients were randomized to double-blind placebo (n=99) or cariprazine (n=101). Time to relapse was significantly longer in cariprazine- versus placebo-treated patients (P=.0010, log-rank test). Relapse occurred in 24.8% of cariprazine- and 47.5% of placebo-treated patients (hazard ratio [95% CI]=0.45 [0.28, 0.73]). Akathisia (19.2%), insomnia (14.4%), and headache (12.0%) were reported in ≥10% of patients during open-label treatment; there were no cariprazine adverse events ≥10% during double-blind treatment. Long-term cariprazine treatment was significantly more effective than placebo for relapse prevention in patients with schizophrenia. The long-term safety profile in this study was consistent with the safety profile observed in previous cariprazine clinical trials. ClincalTrials.gov identifier: NCT01412060.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.schres.2016.06.030

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 27

  1. Arato, 2002, A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study, Int. Clin. Psychopharmacol., 17, 207, 10.1097/00004850-200209000-00001 · DOI · Paper page
  2. Axelrod, 1993, Validation of the 16-item Negative Symptom Assessment, J. Psychiatr. Res., 27, 253, 10.1016/0022-3956(93)90036-2 · DOI
  3. Barnes, 1989, A rating scale for drug-induced akathisia, Br. J. Psychiatry, 154, 672, 10.1192/bjp.154.5.672 · DOI · Paper page
  4. Beasley, 2003, A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse, J. Clin. Psychopharmacol., 23, 582, 10.1097/01.jcp.0000095348.32154.ec · DOI · Paper page
  5. Durgam, 2014, An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial, Schizophr. Res., 152, 450, 10.1016/j.schres.2013.11.041 · DOI · Paper page
  6. Durgam, 2015, Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase III randomized, double-blind, placebo- and active-controlled trial, J. Clin. Psychiatry, 76, e1574, 10.4088/JCP.15m09997 · DOI · Paper page
  7. Emsley, 2013, The nature of relapse in schizophrenia, BMC Psychiatry, 13, 50, 10.1186/1471-244X-13-50 · DOI · Paper page
  8. Graff-Guerrero, 2009, The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO, Arch. Gen. Psychiatry, 66, 606, 10.1001/archgenpsychiatry.2009.43 · DOI · Paper page
  9. Gyertyán, 2008, Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. Behavioural characterisation of RG-15, Naunyn Schmiedeberg's Arch. Pharmacol., 378, 529, 10.1007/s00210-008-0311-x · DOI
  10. Gyertyán, 2011, Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents, Neurochem. Int., 59, 925, 10.1016/j.neuint.2011.07.002 · DOI
  11. Kane, 2007, Treatment strategies to prevent relapse and encourage remission, J. Clin. Psychiatry, 68, 27
  12. Kane, 2011, A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment, J. Clin. Psychiatry, 72, 349, 10.4088/JCP.10m06306 · DOI · Paper page
  13. Kane, 2015, Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial, J. Clin. Psychopharmacol., 35, 1, 10.1097/JCP.0000000000000346 · DOI · Paper page
  14. Kay, 1987, The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophr. Bull., 13, 261, 10.1093/schbul/13.2.261 · DOI · Paper page
  15. Kiss, 2008, Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. Neurochemical characterisation of RG-15, Naunyn Schmiedeberg's Arch. Pharmacol., 378, 515, 10.1007/s00210-008-0308-5 · DOI
  16. Kiss, 2010, Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile, J. Pharmacol. Exp. Ther., 333, 328, 10.1124/jpet.109.160432 · DOI · Paper page
  17. Laszy, 2005, Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats, Psychopharmacology, 179, 567, 10.1007/s00213-004-2096-z · DOI
  18. Lehman, 2004, Practice guideline for the treatment of patients with schizophrenia, second edition, Am. J. Psychiatry, 161, 1
  19. Leucht, 2006, Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia, J. Clin. Psychiatry, 67, 3
  20. Mizrahi, 2011, Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO, Schizophr. Res., 131, 63, 10.1016/j.schres.2011.05.005 · DOI
  21. Morken, 2008, Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia, BMC Psychiatry, 8, 32, 10.1186/1471-244X-8-32 · DOI · Paper page
  22. Nakamura, 2016, Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment), Drug Des. Dev. Ther., 10, 327, 10.2147/DDDT.S95100 · DOI
  23. Pigott, 2003, Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study, J. Clin. Psychiatry, 64, 1048, 10.4088/JCP.v64n0910 · DOI · Paper page
  24. Schwartz, 2000, Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions, Brain Res. Brain Res. Rev., 31, 277, 10.1016/S0165-0173(99)00043-0 · DOI · Paper page
  25. Simpson, 1970, A rating scale for extrapyramidal side effects, Acta Psychiatr. Scand .Suppl., 212, 11, 10.1111/j.1600-0447.1970.tb02066.x · DOI · Paper page
  26. Taylor, 2009, Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review, Br. J. Psychiatry Suppl., 52, S13, 10.1192/bjp.195.52.s13 · DOI · Paper page
  27. Taylor, 2005, Towards consensus in the long-term management of relapse prevention in schizophrenia, Hum. Psychopharmacol., 20, 175, 10.1002/hup.675 · DOI · Paper page

Cited by

See all 101

Metadata

Authors
Durgam, S., Earley, W., Li, R., Li, D., Lu, K., Laszlovszky, I., Fleischhacker, W. W., & Nasrallah, H. A.
Venue
Schizophrenia Research
Publisher
Elsevier BV
Published
2016-10
Volume
176
Issue
2-3
Pages
264-271
ISSN
0920-9964 (ISSN-L)
OpenAlex
W2482680139
Cited by
101
References
7
FWCI
7.24
Type
journal article
Language
en
Update notices
erratum (2018-02-01)
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/j.schres.2016.06.030
The paper
Durgam, S., Earley, W., Li, R., Li, D., Lu, K., Laszlovszky, I., Fleischhacker, W. W., & Nasrallah, H. A. (2016). Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Schizophrenia Research. https://doi.org/10.1016/j.schres.2016.06.030

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.